Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thrombotic microangiopathy following CAR T-cell therapy: a case series from the EBMT Complications Working Party.

Haematologica·2026

Same author

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Frontiers in immunology·2026

Same author

Kidney Transplantation after Clearing Anti-HLA Antibodies with CD19 CAR T Cells.

The New England journal of medicine·2026

Same author

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.

Bone marrow transplantation·2026

Same author

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

Bone marrow transplantation·2026

Same author

Central nervous system complications after allogeneic haematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee on epidemiology, outcome and neuroimaging.

Bone marrow transplantation·2026

Search research articles

Related Experiment Video

Updated: Nov 29, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Complications after CD19+ CAR T-Cell Therapy.

Olaf Penack¹, Christian Koenecke²

¹Department for Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Campus Virchow Clinic, Augustenburger Platz, 113353 Berlin, Germany.

|November 24, 2020

Summary

Chimeric antigen receptor (CAR) T-cell therapy shows efficacy but carries risks. Post-approval studies reveal short- and medium-term side effects, including cytokine release syndrome and neurotoxicity, requiring careful management.

Keywords:

CAR T-cells CD19 chimeric antigen receptor complications cytokine release syndrome leukemia lymphoma toxicity

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Nov 29, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

CD19+ chimeric antigen receptor (CAR) T-cells are effective cancer treatments.
Initial clinical trials did not fully define the complete risk profile of CAR T-cells.
Post-approval studies reveal emerging short- and medium-term effects previously unknown.

Purpose of the Study:

To review the incidence and management of CD19+ CAR T-cell complications.
To highlight frequently occurring adverse events associated with CAR T-cell therapy.
To discuss the potential for broader organ system involvement and long-term complications.

Main Methods:

Review of post-approval studies and clinical data on CD19+ CAR T-cell therapy.
Analysis of reported short-term and medium-term adverse events.
Examination of pre-clinical and clinical data on CAR T-cell-related toxicities.

Main Results:

Frequently occurring events include cytokine release syndrome, neurotoxicity, cardiotoxicity, pulmonary toxicity, metabolic complications, secondary macrophage-activation syndrome, and prolonged cytopenia.
Evidence suggests CAR T-cell toxicities can affect any organ system.
Potential for long-term complications is an area of ongoing investigation.

Conclusions:

CD19+ CAR T-cell therapy requires comprehensive understanding and management of its risk profile.
Ongoing research is crucial for elucidating the pathophysiology and mitigating long-term complications.
Effective management strategies are essential for optimizing patient outcomes in CAR T-cell therapy.